Diabetes

With a broad research focus on heart disease risk reduction through the development of novel treatment strategies, Stephen Nicholls, MBBS, PhD, Monash University and Victorian Heart Hospital, Melbourne, Australia. discusses contributions in the space from therapies with systemwide effects.

An analysis of electronic health record data recorded from 2018-2022 within Duke University Medical Center–affiliated diabetes care centers suggests the increased rate of new-onset type 1 and type 2 diabetes observed during the first year of the pandemic persisted through 2022.

While the overall age-adjusted mortality rate for diabetes and cardiovascular disease (CVD) declined between 1999 and 2019, researchers found an average annual 1% increase since 2014.

According to a Kaiser Family Foundation analysis, 22% of Medicare Part D drug spending in 2021 went towards the 10 top-selling prescription drugs alone.

There may be significant differences in kidney disease between individuals with type 1 diabetes (T1D) and type 2 diabetes (T2D).

Late-breaking results of the COORDINATE-Diabetes trial were presented today at the American Diabetes Association (ADA) 83rd Scientific Sessions in San Diego, California.

New estimates predict that type 2 diabetes prevalence will more than double in the next 30 years, from 529 million people in 2021 to at least 1.3 billion in 2050.

Yesterday’s FDA approvals of a new indication for empagliflozin and combination empagliflozin with metformin hydrochloride for pediatric type 2 diabetes (T2D) provide a new class of oral drugs to treat the condition in children.

Among a small cohort of healthy Korean male volunteers, evogliptin combined with empagliflozin or dapagliflozin had no significant effects on the pharmacokinetics (PK) of each drug.

According to a spokesperson, Merck is prepared to take the lawsuit to the Supreme Court as it challenges drug price negotiations as part of the Inflation Reduction Act.

The authors examined the association of diabetes with self-reported gaps in care coordination and self-reported preventable adverse events using data from a national sample of older adults.

Amal Agarwal, DO, MBA, chief clinical officer at Monogram Health, explains the importance of value-based agreements in dialysis care, and the issue of dialysis prevalence among low-income and marginalized communities.

This article describes facilitators of and barriers to uptake of the underutilized Medicare Diabetes Prevention Program from the perspectives of health care providers and program suppliers in western Pennsylvania.

Using propensity score matching in a US nationally representative sample, authors found the effect of nonadherence to diabetes guidelines on health care expenditures of patients with diabetes.

A review of 24 meta-analyses supported the need for additional monitoring of patients with diabetes and COVID-19, especially if they have comorbidities associated with diabetes.

Authors offered specific recommendations for improving publishing and adoption of algorithmic processes focused on type 2 diabetes (T2D) going forward.

Knowledge is limited on the potential exclusion from pay-for-performance (P4P) programs of patients living with diabetes who have with individual or neighborhood social risks.

Study authors said the findings could inform clinicians when selecting therapies for patients with type 2 diabetes (T2D). However, an editorial found the follow-up period too short and differences between the study arms too small to be meaningful.

Diabetes risk perception was linked to increased TV watching and 1 less day per week of at least 60 minutes of exercise, and was not associated with nutrition or weight loss attempts among adolescents.

Investigators said data show social factors are intertwined with health outcomes.

Researchers are beginning work on a double-blind randomized controlled trial to test the results of this preliminary study.

The risk of incident diabetes was found to be 17% greater in individuals who had COVID-19, and it was higher among men and individuals with severe COVID-19.

The weight loss surgery may help reverse peripheral neuropathy and improve the stability of cardiovascular autonomic neuropathy and retinopathy in individuals with class II/III obesity.

Banner|Aetna's partnership with Virta and their diabetes reversal program brings to light the possibility for expansion to other health issues.

Researchers developed a reliable prediction model for kidney function decline in adults with type 2 diabetes and early to moderately progressed chronic kidney disease, which was externally validated and made publicly available via a web-based application.

Banner|Aetna has partnered with Virta and their diabetes reversal program, which now has data on outcomes and patient populations served so far.

The 2021 recommendations for diabetes and prediabetes screening led to a 14.8% proportionate increase in the total US population eligible for screening, compared with the 2015 guidelines.

For employers, keeping members engaged with their health care is one of the key factors that leads to better outcomes, said Jeremy Wigginton, MD, vice president of health quality and innovation at Blue Cross and Blue Shield of Louisiana.

An analysis of more than 500,000 pregnancies over a 15-year period suggests much of the increase in gestational diabetes rates observed during the study period can be attributed to changes in screening practices.

New research suggests older adults with both diabetes and edentulism are more likely to experience worse and faster cognitive decline compared with adults without either condition and adults older in age.